Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:HURA NASDAQ:IMRX NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$3.42+1.8%$3.23$1.95▼$5.89$129.17M-0.32180,073 shs48,828 shsHURATuHURA Biosciences$2.91-2.3%$2.59$1.80▼$8.40$145.65M0.04306,220 shs141,135 shsIMRXImmuneering$4.50+31.2%$3.46$1.01▼$4.69$163.44M0.371.25 million shs5.66 million shsOKUROnKure Therapeutics$2.74+0.4%$2.40$1.70▼$20.00$36.82M0.4113,059 shs36,180 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux-2.04%+5.00%-4.27%+34.94%+64.71%HURATuHURA Biosciences-0.67%+4.93%+16.86%-1.00%+297,999,900.00%IMRXImmuneering+2.39%+6.52%-19.10%+136.55%+220.56%OKUROnKure Therapeutics-0.36%+13.75%+17.67%+26.98%+272,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNLXGenelux1.4777 of 5 stars3.62.00.00.01.40.00.0HURATuHURA Biosciences1.6134 of 5 stars3.70.00.00.02.10.00.0IMRXImmuneering3.5591 of 5 stars3.34.00.00.01.95.00.6OKUROnKure Therapeutics3.189 of 5 stars3.60.00.00.02.72.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 3.20Buy$17.75419.01% UpsideHURATuHURA Biosciences 3.40Buy$12.67335.28% UpsideIMRXImmuneering 2.60Moderate Buy$13.25194.44% UpsideOKUROnKure Therapeutics 3.14Buy$32.331,080.05% UpsideCurrent Analyst Ratings BreakdownLatest OKUR, IMRX, GNLX, and HURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.008/13/2025OKUROnKure TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025IMRXImmuneeringMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.006/18/2025IMRXImmuneeringChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.006/18/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMRXImmuneeringNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K12,917.34N/AN/A$0.63 per share5.43HURATuHURA BiosciencesN/AN/AN/AN/A$0.38 per shareN/AIMRXImmuneering$320K510.75N/AN/A$0.80 per share5.63OKUROnKure TherapeuticsN/AN/AN/AN/A$5.79 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%N/AHURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A-248.79%-150.83%10/6/2025 (Estimated)IMRXImmuneering-$61.04M-$1.89N/AN/AN/AN/A-146.28%-117.22%N/AOKUROnKure Therapeutics-$52.67M-$4.80N/AN/AN/AN/A-60.52%-55.43%11/6/2025 (Estimated)Latest OKUR, IMRX, GNLX, and HURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025HURATuHURA Biosciences-$0.14-$0.21-$0.07-$0.21N/AN/A8/13/2025Q2 2025IMRXImmuneering-$0.40-$0.40N/A-$0.40N/AN/A8/12/2025Q2 2025OKUROnKure Therapeutics-$1.23-$1.14+$0.09-$1.14N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A4.184.18HURATuHURA BiosciencesN/A0.833.00IMRXImmuneeringN/A3.703.70OKUROnKure TherapeuticsN/A11.1311.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%HURATuHURA Biosciences0.62%IMRXImmuneering67.65%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipGNLXGenelux8.80%HURATuHURA Biosciences0.20%IMRXImmuneering22.90%OKUROnKure Therapeutics2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableHURATuHURA BiosciencesN/A50.05 million49.95 millionN/AIMRXImmuneering6036.32 million28.00 millionNot OptionableOKUROnKure TherapeuticsN/A13.51 million13.20 millionN/AOKUR, IMRX, GNLX, and HURA HeadlinesRecent News About These CompaniesCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19 at 7:44 AM | finance.yahoo.comCompanies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite RiskyAugust 19 at 7:44 AM | finance.yahoo.comLeerink Partnrs Has Positive Forecast for OKUR Q3 EarningsAugust 16, 2025 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and AbCellera Biologics (ABCL)August 15, 2025 | theglobeandmail.comOnKure Therapeutics reports Q2 EPS ($1.14), consensus ($1.25)August 12, 2025 | msn.comOnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business UpdateAugust 12, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comBuy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial PositionJune 3, 2025 | tipranks.comInsider Selling: OnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Sells 1,813,439 Shares of StockMay 20, 2025 | insidertrades.comOnKure Therapeutics (NASDAQ:OKUR) Major Shareholder Cormorant Asset Management, Lp Sells 24,300 SharesMay 15, 2025 | insidertrades.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comPromising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure increased R&D spending in 1Q with drug trials underwayMay 7, 2025 | bizwest.comBOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comOnKure Therapeutics (OKUR) Receives Outperform Rating from Evercore ISI | OKUR Stock NewsApril 30, 2025 | gurufocus.comOnKure Therapeutics, Inc. Class A Common Stock (OKUR) ChartsApril 16, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOKUR, IMRX, GNLX, and HURA Company DescriptionsGenelux NASDAQ:GNLX$3.42 +0.06 (+1.79%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.TuHURA Biosciences NASDAQ:HURA$2.91 -0.07 (-2.35%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Immuneering NASDAQ:IMRX$4.50 +1.07 (+31.20%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.OnKure Therapeutics NASDAQ:OKUR$2.74 +0.01 (+0.37%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Rocket Lab Stock: Breakout Brewing or Time for Patience? Monster Is Re-Energized: Can the Stock's Rally Continue? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access